News
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
14h
Zacks Investment Research on MSNAmgen Looks to Take Share of Booming Obesity Space: Will It Succeed?Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the ...
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...
StockStory.org on MSN1d
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results